News flash it was always the same time tables for FDA approval except for the time spent optimizing. So the only thing which has changed is the time to optimize the readings to get the percentages up a bit. Strange how you suddenly realized how an FDA trial timeline works now for the first time so deep into the game here. Even stranger is how EXAS needed two years plus for their trial yet have an enterprise value 25 times higher that BMOD's. Guess they were luckier to find investors who understand how FDA trials work. Same with the 500+ Biotechs who are all going through trials that will take years yet also have market caps 10-100 times higher than BMOD's. Biotechs are valued off their future earnings potential.